OTCM
HLNCF
Market cap39bUSD
Oct 08, Last price
4.58USD
1D
2.35%
1Q
-5.28%
IPO
31.47%
Name
HALEON PLC
Chart & performance
P/E
18.27
P/S
2.76
EPS
0.19
Div yield, %
2.06%
Shrs. gr., 5y
14.31%
Rev. gr., 5y
2.20%
Revenues
11.03b
-1.82%
Net income
1.67b
+15.58%
CFO
2.34b
+1.55%
Dividend
Aug 14, 20260.0325 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.
Related entities
Subsidiaries (15)
HALEON UK ENTERPRISES LIMITED
HALEON UK EXPORT LIMITED
HALEON UK FINANCE LIMITED
HALEON UK HOLDING CANADA LIMITED
HALEON UK HOLDINGS (NO.1) LIMITED
HALEON UK HOLDINGS (NO.2) LIMITED
HALEON UK HOLDINGS LIMITED
HALEON UK SERVICES LIMITED
HALEON UK TRADING SERVICES LIMITED
HALEON CH SARL
HALEON NETHERLANDS CAPITAL B.V.
HALEON UK CAPITAL PLC
HALEON UK IP LIMITED
HALEON UK TRADING LIMITED
HALEON US CAPITAL LLC
Headquarters & legal address
BUILDING 5, FIRST FLOOR, THE HEIGHTS
WEYBRIDGE, SRY KT13 0NY
GB
WEYBRIDGE, SRY KT13 0NY
GB
Previous name
DRVW 2022 LIMITED
Previous name
DRVW 2022 PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||